ACLX•benzinga•
Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention
Summary
Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 12, 2025 by benzinga